Latest News and Press Releases
Want to stay updated on the latest news?
-
København, 2014-07-01 08:30 CEST (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) meddeler, at Helle Skov (54 år) er udnævnt til ny Executive Vice President (Product Supply)...
-
Copenhagen, 2014-07-01 08:30 CEST (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) announces the appointment of Helle Skov (54 years) as new Executive Vice President (Product...
-
Copenhagen, 2014-06-16 09:00 CEST (GLOBE NEWSWIRE) -- Based on the available data, Torii expects to submit a registration application to the authorities within the next six-to-ten...
-
København, 2014-06-16 09:00 CEST (GLOBE NEWSWIRE) -- På baggrund af de tilgængelige data forventer Torii at indsende en registreringsansøgning til sundhedsmyndighederne inden for de næste...
-
København, 2014-06-09 13:45 CEST (GLOBE NEWSWIRE) -- Første sublinguale tabletvaccine med robuste resultater inden for allergisk rhinitis og allergisk astma. Resultaterne muliggør...
-
Copenhagen, 2014-06-09 13:45 CEST (GLOBE NEWSWIRE) -- First sublingual allergy immunotherapy tablet with robust results in allergic rhinitis and allergic asthma. Data supports European...
-
Copenhagen, 2014-06-03 14:00 CEST (GLOBE NEWSWIRE) -- ALK today announced that the Company will present at the Goldman Sachs 35th Annual Global Healthcare Conference in Palos Verdes, CA....
-
Copenhagen, 2014-05-27 14:00 CEST (GLOBE NEWSWIRE) -- ALK today announced that the Company will present at the Jefferies 2014 Global Healthcare Conference in New York, NY. Jens Bager,...
-
Copenhagen, 2014-05-15 13:00 CEST (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that its ragweed sublingual allergy immunotherapy tablet, which is licensed...
-
København, 2014-05-15 13:00 CEST (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) meddeler i dag, at den sublinguale tabletbaserede vaccine mod ragweedallergi, som ALK har...